Cargando…

Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer

BACKGROUND: Intra-tumor heterogeneity is a potential cause for failure of targeted therapy in gastric cancer, but the extent of heterogeneity of established (HER2) or potential (EGFR, CCND1) target genes and prognostic gene alterations (MYC) had not been systematically studied. METHODS: To study het...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stahl, Phillip, Seeschaaf, Carsten, Lebok, Patrick, Kutup, Asad, Bockhorn, Maximillian, Izbicki, Jakob R, Bokemeyer, Carsten, Simon, Ronald, Sauter, Guido, Marx, Andreas H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324419/ https://www.ncbi.nlm.nih.gov/pubmed/25649416 http://dx.doi.org/10.1186/s12876-015-0231-4

Ejemplares similares

Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancer
por: Melling, Nathaniel, et al.
Publicado: (2015)

ALCAM (CD166) Expression and Serum Levels in Pancreatic Cancer
por: Tachezy, Michael, et al.
Publicado: (2012)

Amplification of the EGFR and CCND1 Are Coordinated and Play Important Roles in the Progression of Oral Squamous Cell Carcinomas
por: Chien, Huei-Tzu, et al.
Publicado: (2019)

FOXO1 overexpression and loss of pSerine256-FOXO1 expression predicts clinical outcome in esophageal adenocarcinomas
por: Grupp, Katharina, et al.
Publicado: (2018)

Genetic aberrations of c-myc and CCND1 in the development of invasive bladder cancer
por: Watters, A D, et al.
Publicado: (2002)

Anaplastic multiple myeloma with amplification of the IGH-CCND1 gene fusion
por: Alencar, Rafael Nobrega, et al.
Publicado: (2023)

Peripheral position of CCND1 and HER-2/neu oncogenes within chromosome territories in esophageal and gastric cancers non-related to amplification and overexpression
por: Bizari, Lucimari, et al.
Publicado: (2009)

Role of CCND1 and C-MYC oncogenes in metastatic breast cancer patients treated by herceptin
por: Trojanec, R, et al.
Publicado: (2011)

Double-Hit Primary Plasma Cell Leukemia with IGH/MYC and IGH/CCND1 Translocations
por: Yasumi, Masato, et al.
Publicado: (2020)

Oesophageal cancer and amplification of the human cyclin D gene CCND1/PRAD1.
por: Adélaide, J., et al.
Publicado: (1995)

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification
por: Meedendorp, Arenda D., et al.
Publicado: (2018)

GATAD1 gene amplification promotes glioma malignancy by directly regulating CCND1 transcription
por: Zhang, Shanshan, et al.
Publicado: (2019)

CCND1 Amplification in Breast Cancer -associations With Proliferation, Histopathological Grade, Molecular Subtype and Prognosis
por: Valla, Marit, et al.
Publicado: (2022)

Dissecting transcriptional amplification by MYC
por: Nie, Zuqin, et al.
Publicado: (2020)

CD5-negative Blastoid Variant Mantle Cell Lymphoma with Complex CCND1/IGH and MYC Aberrations
por: Seok, Yoonmi, et al.
Publicado: (2012)

Loss of 4q21.23-22.1 Is a Prognostic Marker for Disease Free and Overall Survival in Non-Small Cell Lung Cancer
por: Uzunoglu, Faik G., et al.
Publicado: (2014)

Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma
por: KATO, HIROAKI, et al.
Publicado: (2013)

HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts
por: Eriksson, Pontus, et al.
Publicado: (2017)

MYC amplification in leukemia detected by cytogenetics
por: Safranauskas, Roberta Maria da Silva Oliveira, et al.
Publicado: (2021)

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
por: Tanizaki, J, et al.
Publicado: (2011)

MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy
por: Holien, Toril, et al.
Publicado: (2015)

Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer
por: Ismail, Manal F., et al.
Publicado: (2009)

Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma
por: Takeshita, H, et al.
Publicado: (2010)

CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors
por: Chen, Yu, et al.
Publicado: (2020)

Cyclin D1 overexpression in Algerian breast cancer women: correlation with CCND1 amplification and clinicopathological parameters
por: Mohammedi, Latifa, et al.
Publicado: (2019)

CCND1 Amplification Profiling Identifies a Subtype of Melanoma Associated With Poor Survival and an Immunosuppressive Tumor Microenvironment
por: Liu, Jun, et al.
Publicado: (2022)

Breast cancers with EGFR and HER2 co-amplification favor distant metastasis and poor clinical outcome
por: Guo, Peng, et al.
Publicado: (2017)

p53 overexpression is a prognosticator of poor outcome in esophageal cancer
por: Melling, Nathaniel, et al.
Publicado: (2019)

CHAF1A interacts with TCF4 to promote gastric carcinogenesis via upregulation of c-MYC and CCND1 expression
por: Zheng, Lixin, et al.
Publicado: (2018)

Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer
por: Kwak, Yoonjin, et al.
Publicado: (2017)

Recurrent copy number alterations involving EGFR , CDKN2A , and CCND1 in oral premalignant lesions
por: Jäwert, Fredrik, et al.
Publicado: (2022)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan, Jiadi, et al.
Publicado: (2021)

Correction: MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy
por: Holien, Toril, et al.
Publicado: (2018)

Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome
por: Grupp, Katharina, et al.
Publicado: (2018)

Detection of MYC gene amplification in malignant lymphomas.
por: Park, C. K., et al.
Publicado: (1998)

MYC amplifications are common events in childhood osteosarcoma
por: De Noon, Solange, et al.
Publicado: (2021)

Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer
por: Lundgren, Katja, et al.
Publicado: (2008)

LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC
por: Liu, Dongcheng, et al.
Publicado: (2022)

Identification of BRAF, CCND1, and MYC mutations in a patient with multiple primary malignant tumors: a case report and review of the literature
por: Liu, Zheyu, et al.
Publicado: (2023)

MYC gene amplification is a rare event in atypical fibroxanthoma and pleomorphic dermal sarcoma
por: Gaiser, Timo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jro6s48kh8v5r8m24h1i3mo5j5